Evonik stock holds near yearly high as investors digest latest figures

Published on 09/09/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock traded around EUR 18.37 on Xetra as of September 8, 2026, close to its recent 12.84 percent gain over the past year. The chemicals group’s latest reported results and analyst coverage frame the debate over margins and growth.

Fotorealistisches Luftbild eines Spezialchemiewerks mit Destillationstürmen bei Sonnenuntergang — Evonik Industries DE000EVNK013 zeigt ein fotorealistisches Luftbild eines großen Spezialchemiewerks bei Abenddämmerung, Illustration mit AI erstellt.

Evonik Industries AG stock (ISIN DE000EVNK013) was quoted at about EUR 18.37 on Xetra on September 8, 2026, marking a gain of 12.84 percent over the past twelve months for investors who bought a year earlier, based on German market data. According to a performance overview from finanzen.ch, the current value of a hypothetical EUR 1,000 investment made one year ago would stand at roughly EUR 1,128.38 as of September 8, 2026.

One-year performance and valuation picture

The same finanzen.ch calculation shows that the 12.84 percent increase in the Evonik share price over the past year is driven by a move from an implied level near EUR 16.28 to EUR 18.37, underlining that the stock has delivered a positive total return in a period of mixed sentiment for chemicals stocks. The performance figure is computed on price appreciation alone and does not include potential dividend payments, which would further lift the total return for long-term shareholders according to finanzen.ch on September 9, 2026.

While the precise 52-week high and low were not highlighted in the same overview, the one-year gain of 12.84 percent places Evonik in the upper half of the MDAX performance table for the period, suggesting that investors have rewarded the company’s recent operating progress and portfolio focus. For investors, that number is a simple benchmark: Evonik stock has outpaced a flat or slightly negative broader German mid-cap universe over the past twelve months, even without assuming dividend reinvestment.

Latest reported figures and margin focus

Evonik’s investor-relations pages emphasize that the group is covered by a broad range of German and international analysts who track its revenue, earnings and margin trends on a continuing basis. According to the company’s own share information section on September 9, 2026, Evonik highlights this analyst coverage as a key element of its capital-market communication, but leaves specific estimates and recommendations to the individual houses.

In its most recent half-year and quarterly communications, which investors continue to use as a reference into September 2026, Evonik reported revenue and earnings figures that framed the current debate about profitability. The latest available half-year report for 2026, cited across German financial portals and the company’s investor-relations material, showed that Evonik generated multi-billion-euro sales with year-on-year changes in the mid-single-digit percent range, while adjusted EBITDA and net income reflected both portfolio improvements and cost inflation; these figures remain the benchmark until the next quarterly update is published, as indicated by the reporting calendar on Evonik.

Analyst perspective and risk factors

German and international banks covering Evonik typically focus on the company’s ability to defend margins in specialty chemicals against raw-material and energy cost volatility, while executing its portfolio streamlining and growth initiatives. As the share page of Evonik notes, each analyst provides independent research, earnings estimates and price targets, which together form a consensus view of the stock’s risk-reward profile.

Key risk factors regularly cited in analyst reports on chemicals producers like Evonik include exposure to cyclical industrial demand, sensitivity to energy prices in Europe, and execution risk around restructuring or portfolio changes. Against this backdrop, the stock’s 12.84 percent price gain over the past year suggests that, so far, investors have been willing to look through short-term volatility and focus on cost savings and innovation projects, while remaining alert to potential downturns in key end markets such as automotive, construction and consumer goods.

Evonik stock price and investor takeaway

Evonik stock last closed at about EUR 18.37 on Xetra on September 8, 2026, per German market data cited in the finanzen.ch performance overview, representing the reference price for the MDAX-listed chemicals group and giving a clear snapshot of how the market currently values its earnings power and strategy.